Results 171 to 180 of about 1,766 (198)
Some of the next articles are maybe not open access.
Indolent T-Lymphoblastic Proliferation in Idiopathic Multicentric Castleman Disease
Acta Haematologica, 2021Benign and polyclonal proliferation of immature T cells in a lymph node with preserved morphological architecture is called indolent T-lymphoblastic proliferation (iT-LBP). Although overall rare, they have been described in association with both benign and malignant disorders including Castleman disease.
Nabin Raj Karki +3 more
openaire +2 more sources
Systemic juvenile idiopathic arthritis mimics multicentric Castleman?s disease
Clinical Rheumatology, 2003An 11-year-old girl presented with fever and a large cervical lymphadenopathy. Indicators of inflammation were remarkable: she had extremely high levels of serum interleukin-6 (IL-6) (398 pg/ml) in addition to hypergammaglobulinemia and hypoalbuminemia. Computed tomography (CT) revealed swollen systemic lymph nodes.
Shinya, Osone +5 more
openaire +2 more sources
REFRACTORY IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: A CASE REPORT
GLOBAL JOURNAL FOR RESEARCH ANALYSIS, 2023Castleman disease (CD) is a rare disease which includes a heterogeneous group of disorders that share morphological features, such as HHV-8-negative idiopathic multicentric CD (iMCD). We describe the case of a man affected by iMCD who develops ascites during anti-IL-6 treatment with siltuximab.
D'Alessio A +4 more
openaire +1 more source
Polynesian Variant Of Idiopathic Multicentric Castleman Disease
Blood, 2013Abstract Multicentric Castleman Disease (MCD) is an uncommon non-clonal lymphoproliferative disease that traditionally has high morbidity and carries a poor prognosis, with median survival of 26-30 months. There has been growing interest in using interleukin-6 (IL-6) as a therapeutic target due to its role in the pathogenesis of MCD.
Shaun Zhai, David Simpson
openaire +1 more source
Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease
Immunotherapy, 2015Human herpes virus-8 (HHV-8)-negative or idiopathic multicentric Castleman disease (iMCD) is a rare and deadly disorder that sits at the nexus of hematology/oncology, virology and immunology. Management of iMCD has been challenging due to limited understanding of etiology and pathogenesis and few treatment options. The recent approvals in North America,
David C, Fajgenbaum, Razelle, Kurzrock
openaire +2 more sources
Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease
European Journal of Haematology, 2021AbstractObjectivesCastleman disease (CD) is a heterogeneous group of disorders involving systemic inflammation and lymphoproliferation. Recently, clonal mutations have been identified in unicentric CD (UCD) and idiopathic multicentric CD (iMCD), suggesting a potential underlying neoplastic process.MethodsPatients with UCD or iMCD with next generation ...
Aaron M. Goodman +8 more
openaire +2 more sources
Five biopsies, one diagnosis: challenges in idiopathic multicentric Castleman disease
BMJ Case Reports, 2020A previously healthy 29-year-old man initially presented to the hospital with pleuritic chest pain and shortness of breath. Over the next 2 months he developed ongoing fevers and night sweats with recurrent exudative pleural effusions and ascites. He had an extensive infectious and autoimmune workup that was unremarkable.
Julie Semenchuk +3 more
openaire +2 more sources
Idiopathic multicentric Castleman disease of TAFRO subtype
British Journal of Haematology, 2021Katherine Godfrey +3 more
openaire +2 more sources
Response assessment and salvage indication for idiopathic multicentric Castleman disease
Leukemia & Lymphoma, 2020I read with great interest the article by Ebisawa et al. on idiopathic multicentric Castleman disease (iMCD) [1].
openaire +2 more sources
Adrenalitis and anasarca in idiopathic multicentric Castleman's disease
The Lancet, 2021Luke Y C, Chen +3 more
openaire +2 more sources